INSPIRE-study (International Neonatal tranSfusion PoInt pREvalence)
Sprache der Bezeichnung:
Englisch
Original Kurzfassung:
Premature neonates are highly transfused patients, though robust evidence supporting neonatal transfusion practice is scarce. Two randomized controlled trials (RCTs) were recently published, indicating no benefit in long-term outcomes when using liberal (high) thresholds for red blood cell (RBC) transfusions. Another RCT, comparing a high and low platelet transfusion threshold, even reported evidence that liberal transfusion treatment (high thresholds) can cause harm. There are no international neonatal transfusion guidelines that have been implemented by Europe as a whole, resulting in significant variation in transfusion practice within Europe. Detailed contemporary data on neonatal transfusion practice in Europe, including neonatal component specifications, are lacking.
This Prospective, European, multicenter, observational point prevalence study in neonates with a gestational age below 32 weeks at birth will provide a picture of current neonatal transfusion practices within Europe, which can be used to improve practice, promote adherence to evidence-based transfusion guidelines, and inform future randomized controlled trials.The main objective is to describe the prevalence, indications, adverse effects, and component specifications of RBC, platelet, and plasma transfusions in preterm neonates. Additionally, to describe the use of local or national guidelines and the evidence-basedness of transfusion practices in preterm neonates.
This study will identify current neonatal transfusion practices that can be improved, and areas with substantial clinical variation which can be targeted in future clinical trials. The resulting data may help reduce unnecessary transfusions through increased awareness of the proper use of transfusions in this vulnerable patient population. This may eventually lead to a reduction in the number of adverse events, lower costs, optimal allocation of donor blood, and ultimately, better long-term neonatal outcomes.